Do analysts prefer AIFC or LRMR?

Larimar Therapeutics has a consensus price target of $12.71, indicating a potential upside of 290.01%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09

Which has better earnings & valuation, AIFC or LRMR?

Larimar Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.38 -$344.51M N/A N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Does the media prefer AIFC or LRMR?

In the previous week, Larimar Therapeutics had 15 more articles in the media than ALT5 Sigma. MarketBeat recorded 16 mentions for Larimar Therapeutics and 1 mentions for ALT5 Sigma. Larimar Therapeutics' average media sentiment score of 0.79 beat ALT5 Sigma's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer AIFC or INDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, AIFC or INDP?

Indaptus Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.38 -$344.51M N/A N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Do analysts rate AIFC or QNCX?

Quince Therapeutics has a consensus target price of $690.00, suggesting a potential upside of 3,904.64%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.20

Which has higher earnings & valuation, AIFC or QNCX?

Quince Therapeutics has lower revenue, but higher earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.38 -$344.51M N/A N/A Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A

Does the media prefer AIFC or QNCX?

In the previous week, Quince Therapeutics had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Quince Therapeutics and 1 mentions for ALT5 Sigma. Quince Therapeutics' average media sentiment score of 0.73 beat ALT5 Sigma's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IMRX or AIFC?

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 217.92%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, IMRX or AIFC?

Immuneering has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A ALT5 Sigma $24.84M 3.38 -$344.51M N/A N/A

Is IMRX or AIFC more profitable?

Immuneering has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Immuneering's return on equity of -31.93% beat ALT5 Sigma's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% ALT5 Sigma -2,483.94% -68.25% -62.43%

Does the media favor IMRX or AIFC?

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Immuneering's average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AIFC or AKBA?

Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than ALT5 Sigma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ALT5 Sigma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Akebia Therapeutics 2 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20

Which has higher valuation & earnings, AIFC or AKBA?

Akebia Therapeutics has higher revenue and earnings than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALT5 Sigma $24.84M 3.38 -$344.51M N/A N/A Akebia Therapeutics $236.20M 1.41 -$5.34M -$0.08 N/A

Does the media prefer AIFC or AKBA?

In the previous week, Akebia Therapeutics had 8 more articles in the media than ALT5 Sigma. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for ALT5 Sigma. Akebia Therapeutics' average media sentiment score of 0.31 beat ALT5 Sigma's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALT5 Sigma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ALT5 Sigma (AIFC) Competitors

$0.60 0.00 (0.00%)

As of 07/2/2026 04:00 PM Eastern

Compare

AIFC vs. LRMR, INDP, QNCX, IMRX, and AKBA

Should you buy ALT5 Sigma stock or one of its competitors? MarketBeat compares ALT5 Sigma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALT5 Sigma include Larimar Therapeutics (LRMR), Indaptus Therapeutics (INDP), Quince Therapeutics (QNCX), Immuneering (IMRX), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.

How does ALT5 Sigma compare to Larimar Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

ALT5 Sigma has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Larimar Therapeutics had 15 more articles in the media than ALT5 Sigma. MarketBeat recorded 16 mentions for Larimar Therapeutics and 1 mentions for ALT5 Sigma. Larimar Therapeutics' average media sentiment score of 0.79 beat ALT5 Sigma's score of 0.00 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Larimar Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Larimar Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.38	-$344.51M	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Larimar Therapeutics has a consensus price target of $12.71, indicating a potential upside of 290.01%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Larimar Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Summary

Larimar Therapeutics beats ALT5 Sigma on 10 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Indaptus Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

ALT5 Sigma has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

In the previous week, ALT5 Sigma had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for ALT5 Sigma and 0 mentions for Indaptus Therapeutics. ALT5 Sigma's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
ALT5 Sigma	Neutral
Indaptus Therapeutics	Neutral

Indaptus Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.38	-$344.51M	N/A	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Indaptus Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by company insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ALT5 Sigma beats Indaptus Therapeutics on 5 of the 9 factors compared between the two stocks.

How does ALT5 Sigma compare to Quince Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Quince Therapeutics has lower revenue, but higher earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.38	-$344.51M	N/A	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

Quince Therapeutics has a consensus target price of $690.00, suggesting a potential upside of 3,904.64%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.20

In the previous week, Quince Therapeutics had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 4 mentions for Quince Therapeutics and 1 mentions for ALT5 Sigma. Quince Therapeutics' average media sentiment score of 0.73 beat ALT5 Sigma's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Quince Therapeutics' return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Quince Therapeutics	N/A	N/A	-67.99%

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ALT5 Sigma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

Quince Therapeutics beats ALT5 Sigma on 11 of the 14 factors compared between the two stocks.

How does ALT5 Sigma compare to Immuneering?

Immuneering (NASDAQ:IMRX) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Immuneering has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Immuneering's return on equity of -31.93% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Immuneering has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
ALT5 Sigma	$24.84M	3.38	-$344.51M	N/A	N/A

Immuneering currently has a consensus price target of $16.50, indicating a potential upside of 217.92%. Given Immuneering's stronger consensus rating and higher possible upside, research analysts clearly believe Immuneering is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Immuneering's average media sentiment score of 0.00 equaled ALT5 Sigma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immuneering has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Summary

Immuneering beats ALT5 Sigma on 10 of the 12 factors compared between the two stocks.

How does ALT5 Sigma compare to Akebia Therapeutics?

ALT5 Sigma (NASDAQ:AIFC) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 276.34%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Akebia Therapeutics had 8 more articles in the media than ALT5 Sigma. MarketBeat recorded 9 mentions for Akebia Therapeutics and 1 mentions for ALT5 Sigma. Akebia Therapeutics' average media sentiment score of 0.31 beat ALT5 Sigma's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALT5 Sigma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALT5 Sigma	$24.84M	3.38	-$344.51M	N/A	N/A
Akebia Therapeutics	$236.20M	1.41	-$5.34M	-$0.08	N/A

ALT5 Sigma has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

Akebia Therapeutics has a net margin of -8.83% compared to ALT5 Sigma's net margin of -2,483.94%. Akebia Therapeutics' return on equity of -62.72% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

6.3% of ALT5 Sigma shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 0.2% of ALT5 Sigma shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Akebia Therapeutics beats ALT5 Sigma on 12 of the 14 factors compared between the two stocks.

Get ALT5 Sigma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIFC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIFC vs. The Competition

Export

Metric	ALT5 Sigma	FIN Industry	Finance Sector	NASDAQ Exchange
Market Cap	$84.07M	$7.21B	$14.10B	$12.47B
Dividend Yield	N/A	4.98%	5.67%	6.51%
P/E Ratio	N/A	17.38	20.59	24.70
Price / Sales	3.38	10.53	43.05	99.69
Price / Cash	N/A	50.14	19.45	57.09
Price / Book	0.07	3.25	2.27	6.46
Net Income	-$344.51M	$303.39M	$1.14B	$337.01M
7 Day Performance	9.31%	0.25%	0.65%	1.69%
1 Month Performance	-5.43%	-0.24%	2.37%	3.81%
1 Year Performance	-92.83%	-2.68%	12.01%	23.90%

ALT5 Sigma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIFC ALT5 Sigma	0.0445 of 5 stars	$0.60 flat	N/A	-92.8%	$84.07M	$24.84M	N/A	170	News Coverage Gap Up
LRMR Larimar Therapeutics	3.1615 of 5 stars	$3.21 +5.2%	$13.17 +310.2%	+3.8%	$333.46M	N/A	N/A	30	News Coverage Analyst Forecast Analyst Revision
INDP Indaptus Therapeutics	0.2293 of 5 stars	$2.94 -2.0%	N/A	-70.4%	$332.93M	N/A	N/A	6
QNCX Quince Therapeutics	3.2943 of 5 stars	$16.75 -7.9%	$690.00 +4,019.4%	-94.6%	$327.63M	N/A	N/A	60	News Coverage Stock Split Gap Down
IMRX Immuneering	2.553 of 5 stars	$5.05 +1.2%	$16.50 +226.7%	+53.1%	$326.74M	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIFC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALT5 Sigma (AIFC) Competitors

AIFC vs. LRMR, INDP, QNCX, IMRX, and AKBA

How does ALT5 Sigma compare to Larimar Therapeutics?

Summary

How does ALT5 Sigma compare to Indaptus Therapeutics?

Summary

How does ALT5 Sigma compare to Quince Therapeutics?

Summary

How does ALT5 Sigma compare to Immuneering?

Summary

How does ALT5 Sigma compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALT5 Sigma (AIFC) Competitors

AIFC vs. LRMR, INDP, QNCX, IMRX, and AKBA

How does ALT5 Sigma compare to Larimar Therapeutics?

Which has more risk & volatility, AIFC or LRMR?

Do institutionals & insiders believe in AIFC or LRMR?

Does the media prefer AIFC or LRMR?

Is AIFC or LRMR more profitable?

Which has better earnings & valuation, AIFC or LRMR?

Do analysts prefer AIFC or LRMR?

Summary

How does ALT5 Sigma compare to Indaptus Therapeutics?

Which has more risk and volatility, AIFC or INDP?

Does the media favor AIFC or INDP?

Which has preferable earnings & valuation, AIFC or INDP?

Is AIFC or INDP more profitable?

Do analysts prefer AIFC or INDP?

Do insiders & institutionals believe in AIFC or INDP?

Summary

How does ALT5 Sigma compare to Quince Therapeutics?

Which has higher earnings & valuation, AIFC or QNCX?

Do analysts rate AIFC or QNCX?

Does the media prefer AIFC or QNCX?

Is AIFC or QNCX more profitable?

Do institutionals & insiders hold more shares of AIFC or QNCX?

Which has more risk & volatility, AIFC or QNCX?

Summary

How does ALT5 Sigma compare to Immuneering?

Is IMRX or AIFC more profitable?

Which has better valuation & earnings, IMRX or AIFC?

Do analysts rate IMRX or AIFC?

Do institutionals & insiders have more ownership in IMRX or AIFC?

Does the media favor IMRX or AIFC?

Which has more volatility and risk, IMRX or AIFC?

Summary

How does ALT5 Sigma compare to Akebia Therapeutics?

Do analysts rate AIFC or AKBA?

Does the media prefer AIFC or AKBA?

Which has higher valuation & earnings, AIFC or AKBA?

Which has more volatility and risk, AIFC or AKBA?

Is AIFC or AKBA more profitable?

Do institutionals & insiders hold more shares of AIFC or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIFC vs. The Competition

ALT5 Sigma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools